{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:49:03Z","timestamp":1793429343281,"version":"4.5.0"},"reference-count":250,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013057","name":"Heffter Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA003889"],"award-info":[{"award-number":["R01DA003889"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R03DA042336"],"award-info":[{"award-number":["R03DA042336"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.pharmthera.2018.11.010","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T21:29:09Z","timestamp":1543872549000},"page":"83-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":439,"special_numbering":"C","title":["Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function"],"prefix":"10.1016","volume":"197","author":[{"given":"Matthew W.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick S.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0893-133X(95)00136-2","article-title":"The psychopharmacology of hallucinogens","volume":"14","author":"Abraham","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000468273","article-title":"A review of LSD treatment in alcoholism","volume":"6","author":"Abuzzahab","year":"1971","journal-title":"International Pharmacopsychiatry"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.11.010_bb0015","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/hbm.23150","article-title":"Factors affecting characterization and localization of interindividual differences in functional connectivity using MRI","volume":"37","author":"Airan","year":"2016","journal-title":"Human Brain Mapping"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12231-011-9152-5","article-title":"A prehistoric mural in Spain depicting neurotropic psilocybe mushrooms?","volume":"65","author":"Akers","year":"2011","journal-title":"Economic Botany"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.11.010_bb0025","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1162\/jocn.2009.21322","article-title":"The neural basis for spatial relations","volume":"22","author":"Amorapanth","year":"2010","journal-title":"Journal of Cognitive Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0030","series-title":"Hallucinogenic Drugs and their Psychotherapeutic Use","first-page":"101","article-title":"LSD in the treatment of criminal psychopaths","author":"Arendsen-Hein","year":"1963"},{"issue":"9","key":"10.1016\/j.pharmthera.2018.11.010_bb0035","doi-asserted-by":"crossref","first-page":"e016025","DOI":"10.1136\/bmjopen-2017-016025","article-title":"Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting","volume":"7","author":"Argento","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0040","series-title":"Australia\u2019s Health Series No. 14. Cat. no. AUS 178","article-title":"Australia\u2019s health 2014","author":"Australian Institute of Health and Welfare","year":"2014"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0050","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1196\/annals.1432.003","article-title":"Dextromethorphan","volume":"1139","author":"Banken","year":"2008","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/02791072.2009.10400530","article-title":"A six-month prospective evaluation of personality traits, psychiatric symptoms and quality of life in ayahuasca-naive subjects","volume":"41","author":"Barbosa","year":"2009","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0060","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1037\/0022-3514.51.6.1173","article-title":"The moderator-mediator variable distinction in social psychological research: Conceptual, strategic and statistical considerations","volume":"51","author":"Baron","year":"1986","journal-title":"Journal of Personality and Social Psychology"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0065","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/7854_2017_474","article-title":"Classic hallucinogens and mystical experiences: Phenomenology and neural correlates","volume":"36","author":"Barrett","year":"2017","journal-title":"Current Topics in Behavioral Neurosciences"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.11.010_bb0070","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neubiorev.2013.05.007","article-title":"Interpreting EEG alpha activity","volume":"44","author":"Bazanova","year":"2014","journal-title":"Neuroscience & Biobehavioral Reviews; Applied Neuroscience: Models, Methods, Theories, Reviews A Society of Applied Neuroscience (SAN) Special Issue"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.11.010_bb0080","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/scan\/nsq080","article-title":"Depression, rumination and the default network","volume":"6","author":"Berman","year":"2011","journal-title":"Social Cognitive and Affective Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.11.010_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042421","article-title":"Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: A longitudinal study","volume":"7","author":"Bouso","year":"2012","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00005053-197002000-00003","article-title":"Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: A follow-up study","volume":"150","author":"Bowen","year":"1970","journal-title":"The Journal of Nervous and Mental Disease"},{"issue":"9320","key":"10.1016\/j.pharmthera.2018.11.010_bb0100","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(02)08701-9","article-title":"Mescaline use for 5700 years","volume":"359","author":"Bruhn","year":"2002","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF02862854","article-title":"Early peyote research an interdisciplinary study","volume":"28","author":"Bruhn","year":"1974","journal-title":"Economic Botany"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.11.010_bb0110","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/mol.60.6.1181","article-title":"Amphetamine, 3, 4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor","volume":"60","author":"Bunzow","year":"2001","journal-title":"Molecular pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0115","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.neuron.2013.10.002","article-title":"Scaling brain size, keeping timing: Evolutionary preservation of brain rhythms","volume":"80","author":"Buzsaki","year":"2013","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.brs.2015.08.016","article-title":"Modulation of limbic and prefrontal connectivity by electroconvulsive therapy in treatment-resistant depression: A preliminary study","volume":"9","author":"Cano","year":"2016","journal-title":"Brain Stimulation"},{"issue":"12","key":"10.1016\/j.pharmthera.2018.11.010_bb0125","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0130","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00213-017-4769-4","article-title":"Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Similarities and differences in subjective experiences","volume":"235","author":"Carbonaro","year":"2018","journal-title":"Psychopharmacology (Berlin)"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0135","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.11.010_bb0140","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"The Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.11.010_bb0145","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fnhum.2014.00020","article-title":"The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs","volume":"8","author":"Carhart-Harris","year":"2014","journal-title":"Frontiers in Human Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0155","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1192\/bjp.bp.111.103309","article-title":"Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin","volume":"200","author":"Carhart-Harris","year":"2012","journal-title":"The British Journal of Psychiatry: The Journal of Mental Science"},{"issue":"17","key":"10.1016\/j.pharmthera.2018.11.010_bb0160","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1073\/pnas.1518377113","article-title":"Neural correlates of the LSD experience revealed by multimodal neuroimaging","volume":"113","author":"Carhart-Harris","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0165","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Scientific Reports"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.11.010_bb0170","doi-asserted-by":"crossref","first-page":"489","DOI":"10.33588\/rn.4208.2006040","article-title":"Mescaline and the San Pedro cactus ritual: Archaeological and ethnographic evidence in northern Peru","volume":"42","author":"Carod-Artal","year":"2006","journal-title":"Revista de Neurologia"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb5505","series-title":"2004-2011 Drug Abuse Warning Network","author":"Center for Behavioral Health Statistics and Quality","year":"2012"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb7555","series-title":"Drug Abuse Warning Network methodology report","author":"Center for Behavioral Health Statistics and Quality","year":"2013"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb8585","series-title":"2015 National Survey on Drug Use and Health Public Use File Dataset","author":"Center for Behavioral Health Statistics and Quality","year":"2016"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0175","doi-asserted-by":"crossref","first-page":"577","DOI":"10.15288\/qjsa.1959.20.577","article-title":"Use of d-lysergic acid diethylamide in the treatment of alcoholism","volume":"20","author":"Chwelos","year":"1959","journal-title":"Quarterly Journal of Studies on Alcohol"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00005053-196001000-00005","article-title":"Lysergic acid diethylamide: side effects and complications","volume":"130","author":"Cohen","year":"1960","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"1384","key":"10.1016\/j.pharmthera.2018.11.010_bb0185","first-page":"69","article-title":"LSD and the anguish of dying","volume":"231","author":"Cohen","year":"1965","journal-title":"Harper's Magazine"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0190","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.neuroimage.2010.04.251","article-title":"Nicotine replacement in abstinent smokers improves cognitive withdrawal symptoms with modulation of resting brain network dynamics","volume":"52","author":"Cole","year":"2010","journal-title":"NeuroImage"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0195","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3758\/CABN.10.4.470","article-title":"Neural correlates of rumination in depression","volume":"10","author":"Cooney","year":"2010","journal-title":"Cognitive, Affective & Behavioral Neuroscience"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.11.010_bb0200","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S2215-0366(16)30087-6","article-title":"Altered states: psilocybin for treatment-resistant depression","volume":"3","author":"Cowen","year":"2016","journal-title":"The Lancet Psychiatry"},{"issue":"5994","key":"10.1016\/j.pharmthera.2018.11.010_bb0205","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1126\/science.1194313","article-title":"Neuroscience. A glutamate pathway to faster-acting antidepressants?","volume":"329","author":"Cryan","year":"2010","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2016.08.022","article-title":"The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors","volume":"113","author":"De Gregorio","year":"2016","journal-title":"Pharmacological Research"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.11.010_bb0215","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1162\/jocn_a_00233","article-title":"A meta-analysis of functional neuroimaging studies of self- and other judgments reveals a spatial gradient for mentalizing in medial prefrontal cortex","volume":"24","author":"Denny","year":"2012","journal-title":"Journal of Cognitive Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0220","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pnpbp.2015.02.015","article-title":"Role of calcium, glutamate and NMDA in major depression and therapeutic application","volume":"64","author":"Deutschenbaur","year":"2016","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0225","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jad.2014.09.028","article-title":"A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder","volume":"172","author":"Dichter","year":"2015","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0230","first-page":"1","article-title":"Pahnke's \"Good Friday Experiment\": A long-term follow-up and methodological critique","volume":"23","author":"Doblin","year":"1991","journal-title":"The Journal of Transpersonal Psychology"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0235","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/02791072.2005.10399794","article-title":"Report on psychoactive drug use among adolescents using ayahuasca within a religious context","volume":"37","author":"Doering-Silveira","year":"2005","journal-title":"Journal of Psychoactive Drugs"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0240","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/2045125316638008","article-title":"Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): A systematic review of clinical trials published in the last 25 years","volume":"6","author":"dos Santos","year":"2016","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.11.010_bb0245","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1152\/jn.00895.2010","article-title":"Brain activity at rest: A multiscale hierarchical functional organization","volume":"105","author":"Doucet","year":"2011","journal-title":"Journal of Neurophysiology"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0250","author":"Drug Enforcement Agency"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0255","author":"Drug Enforcement Agency"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0260","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2011.08.044","article-title":"Signaling pathways underlying the rapid antidepressant actions of ketamine","volume":"62","author":"Duman","year":"2012","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tins.2011.11.004","article-title":"Signaling pathways underlying the pathophysiology and treatment of depression: Novel mechanisms for rapid-acting agents","volume":"35","author":"Duman","year":"2012","journal-title":"Trends in Neurosciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2014.10.028","article-title":"Ketamine and other potential glutamate antidepressants","volume":"225","author":"Dutta","year":"2015","journal-title":"Psychiatry Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0275","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/shm\/hkl039","article-title":"\u2018Hitting highs at rock bottom\u2019: LSD treatment for alcoholism, 1950-1970","volume":"19","author":"Dyck","year":"2006","journal-title":"Social History of Medicine"},{"issue":"1-3","key":"10.1016\/j.pharmthera.2018.11.010_bb0280","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jep.2005.04.022","article-title":"Prehistoric peyote use: Alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas","volume":"101","author":"El-Seedi","year":"2005","journal-title":"Journal of Ethnopharmacology"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0285","series-title":"European Drug Report 2016: Trends and Developments","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2016"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0290","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugalcdep.2010.03.024","article-title":"Assessment of addiction severity among ritual users of ayahuasca","volume":"111","author":"F\u00e1bregas","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.11.010_bb0295","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/nn.4135","article-title":"Functional connectome fingerprinting: Identifying individuals using patterns of brain connectivity","volume":"18","author":"Finn","year":"2015","journal-title":"Nature Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0300","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12231-016-9342-2","article-title":"On the origin of the genus psilocybe and its potential ritual use in ancient Africa and Europe","volume":"70","author":"Froese","year":"2016","journal-title":"Economic Botany"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0305","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Garcia-Romeu","year":"2014","journal-title":"Current Drug Abuse Reviews"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.11.010_bb0310","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"The Journal of Nervous and Mental Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1559-1816.1972.tb01259.x","article-title":"Correlates of marijuana use among college students","volume":"2","author":"Gergen","year":"1972","journal-title":"Journal of Applied Social Psychology"},{"issue":"12","key":"10.1016\/j.pharmthera.2018.11.010_bb0320","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/cercor\/bhj113","article-title":"Differential functions of lateral and medial rostral prefrontal cortex (area 10) revealed by brain-behavior associations","volume":"16","author":"Gilbert","year":"2006","journal-title":"Cerebral Cortex (New York, N.Y.: 1991)"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0325","series-title":"Recent Surveys of Nonmedical Drug Use: A Compendium of Abstracts","author":"Glenn","year":"1974"},{"issue":"25","key":"10.1016\/j.pharmthera.2018.11.010_bb0330","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","article-title":"Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents","volume":"35","author":"Glennon","year":"1984","journal-title":"Life Sciences"},{"issue":"2-3","key":"10.1016\/j.pharmthera.2018.11.010_bb0335","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-2999(83)90464-8","article-title":"Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists","volume":"91","author":"Glennon","year":"1983","journal-title":"European Journal of Pharmacology"},{"issue":"26","key":"10.1016\/j.pharmthera.2018.11.010_bb0340","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1523\/JNEUROSCI.23-26-08836.2003","article-title":"Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex","volume":"23","author":"Gonz\u00e1lez-Maeso","year":"2003","journal-title":"Journal of Neuroscience"},{"issue":"06","key":"10.1016\/j.pharmthera.2018.11.010_bb0345","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-2005-916185","article-title":"Psychological effects of (S)-ketamine and N, N-dimethyltryptamine (DMT): A double-blind, cross-over study in healthy volunteers","volume":"38","author":"Gouzoulis-Mayfrank","year":"2005","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.11.010_bb0350","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00008877-199811000-00011","article-title":"Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans","volume":"9","author":"Gouzoulis-Mayfrank","year":"1998","journal-title":"Behavioural Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.11.010_bb0355","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0893-133X(98)00089-X","article-title":"Neurometabolic effects of psilocybin, 3, 4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers: a double-blind, placebo-controlled PET study with [18F] FDG","volume":"20","author":"Gouzoulis-Mayfrank","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0360","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s002130050860","article-title":"Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. results of an experimental double-blind placebo-controlled study","volume":"142","author":"Gouzoulis-Mayfrank","year":"1999","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.11.010_bb0365","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"12","key":"10.1016\/j.pharmthera.2018.11.010_bb0370","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0375","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0380","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produce enduring positive changes in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths","year":"2018","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0385","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0390","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/j.2326-1951.1981.tb01901.x","article-title":"LSD reconsidered","volume":"21","author":"Grinspoon","year":"1981","journal-title":"The Sciences"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0395","series-title":"Psychedelic drugs reconsidered","author":"Grinspoon","year":"1979"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0400","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0405","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.neuroimage.2010.06.066","article-title":"Mesocorticolimbic circuits are impaired in chronic cocaine users as demonstrated by resting-state functional connectivity","volume":"53","author":"Gu","year":"2010","journal-title":"NeuroImage"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0410","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/1751696X.2014.993244","article-title":"Psychoactive substances in prehistoric times: Examining the archaeological evidence","volume":"8","author":"Guerra-Doce","year":"2015","journal-title":"Time & Mind: The Journal of Archaeology, Consciousness & Culture"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0415","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.pharmthera.2018.11.010_bb0420","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1017\/S1461145713000722","article-title":"Serotonergic hallucinogens as translational models relevant to schizophrenia","volume":"16","author":"Halberstadt","year":"2013","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.11.010_bb0425","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1177\/0269881110388326","article-title":"Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice","volume":"25","author":"Halberstadt","year":"2011","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0430","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/16066359609010756","article-title":"The use of hallucinogens in the treatment of addiction","volume":"4","author":"Halpern","year":"1996","journal-title":"Addiction Research"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.11.010_bb0435","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.biopsych.2005.06.038","article-title":"Psychological and cognitive effects of long-term peyote use among Native Americans","volume":"58","author":"Halpern","year":"2005","journal-title":"Biological Psychiatry"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.11.010_bb0440","first-page":"22","article-title":"Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament","volume":"14","author":"Halpern","year":"2008","journal-title":"Medical Science Monitor: International Medical Journal of Experimental and Clinical Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0445","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.11.010_bb0450","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/mp.2011.23","article-title":"Discovering imaging endophenotypes for major depression","volume":"16","author":"Hasler","year":"2011","journal-title":"Molecular Psychiatry"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0455","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/0269881107077734","article-title":"Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N, N-dimethyltryptamine (DMT) models of psychosis","volume":"21","author":"Heekeren","year":"2007","journal-title":"Journal of Psychopharmacology"},{"issue":"5-6","key":"10.1016\/j.pharmthera.2018.11.010_bb0460","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF01825267","article-title":"Beitrag zur chemischen und pharmakologischen Kenntnis der Cacteen","volume":"40","author":"Heffter","year":"1898","journal-title":"Archiv f\u00fcr Experimentelle Pathologie und Pharmakologie"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0465","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/0269881113513851","article-title":"Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision","volume":"28","author":"Hendricks","year":"2014","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0470","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0269881117735685","article-title":"The relationships of classic psychedelic use with criminal behavior in the United States adult population","volume":"32","author":"Hendricks","year":"2018","journal-title":"Journal of Psychopharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2018.11.010_bb0475","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1177\/0269881115598338","article-title":"Psilocybin, psychological distress, and suicidality","volume":"29","author":"Hendricks","year":"2015","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0480","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/0269881114565653","article-title":"Classic psychedelic use is associated with reduced psychological distress and suicidality in the united states adult population","volume":"29","author":"Hendricks","year":"2015","journal-title":"Journal of Psychopharmacology"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.11.010_bb0485","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/0006-3223(92)90059-9","article-title":"Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research","volume":"32","author":"Hermle","year":"1992","journal-title":"Biological Psychiatry"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.11.010_bb0490","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1176\/ajp.107.8.607","article-title":"Experimentally produced psychoses","volume":"107","author":"Hoch","year":"1951","journal-title":"American Journal of Psychiatry"},{"issue":"418","key":"10.1016\/j.pharmthera.2018.11.010_bb0495","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1192\/bjp.100.418.29","article-title":"Schizophrenia: A new approach. II. Result of a year's research","volume":"100","author":"Hoffer","year":"1954","journal-title":"Journal of Mental Science"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0500","series-title":"LSD: My problem child. Translated by Jonathan Ott","author":"Hofmann","year":"1980"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0505","series-title":"LSD: My problem child and insights\/outlooks","author":"Hofmann","year":"2013"},{"issue":"10","key":"10.1016\/j.pharmthera.2018.11.010_bb0510","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1176\/ajp.125.10.1352","article-title":"A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetamine in alcoholics","volume":"125","author":"Hollister","year":"1969","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0515","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/0021-8294.00085","article-title":"Dimensions of the mysticism scale: Confirming the three-factor structure in the United States and Iran","volume":"40","author":"Hood","year":"2001","journal-title":"Journal for the Scientific Study of Religion"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0520","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/1384454","article-title":"The construction and preliminary validation of a measure of reported mystical experience","volume":"14","author":"Hood","year":"1975","journal-title":"Journal for the Scientific Study of Religion"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0525","series-title":"The Psychology of Religion","article-title":"Mysticism","author":"Hood","year":"2009"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0530","series-title":"The perennial philosophy","author":"Huxley","year":"1947"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0535","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00408109","article-title":"Comparison of the reactions induced by psilocybin and LSD-25 in man","volume":"1","author":"Isbell","year":"1959","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0540","series-title":"The varieties of religious experience","author":"James","year":"1902"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0545","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.neuroimage.2011.04.004","article-title":"Amplitude low-frequency oscillation abnormalities in the heroin users: A resting state fMRI study","volume":"57","author":"Jiang","year":"2011","journal-title":"NeuroImage"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0550","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/0269881114568039","article-title":"Psychedelics not linked to mental health problems or suicidal behavior: A population study","volume":"29","author":"Johansen","year":"2015","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0560","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/09540261.2018.1509544","article-title":"Psychiatry might need some psychedelic therapy. Introduction to issue: The renaissance in psychedelic research","volume":"30","author":"Johnson","year":"2018","journal-title":"International Review of Psychiatry"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.11.010_bb0555","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: Guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.11.010_bb0565","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0570","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.11.010_bb0575","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0269881116684335","article-title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use","volume":"31","author":"Johnson","year":"2017","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0580","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of psilocybin","volume":"14","author":"Johnson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1-3","key":"10.1016\/j.pharmthera.2018.11.010_bb0590","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drugalcdep.2011.10.029","article-title":"Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers","volume":"123","author":"Johnson","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0595","series-title":"A report from the Youth in Transition Project for the Institute of Social Research atUniversity of Michigan","article-title":"Drugs and American Youth","author":"Johnston","year":"1973"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0600","series-title":"Philosophy of mysticism: Raids on the ineffable","author":"Jones","year":"2016"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0605","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/BF01575629","article-title":"Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide","volume":"41","author":"Kast","year":"1967","journal-title":"Psychiatric Quarterly"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0610","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1213\/00000539-196405000-00013","article-title":"Study of lysergic acid diethylamide as an analgesic agent","volume":"43","author":"Kast","year":"1964","journal-title":"Anesthesia and Analgesia"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0615","series-title":"Chemical warfare: Secrets almost forgotten","author":"Ketchum","year":"2006"},{"issue":"12","key":"10.1016\/j.pharmthera.2018.11.010_bb0620","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.tics.2012.10.007","article-title":"Alpha-band oscillations, attention, and controlled access to stored information","volume":"16","author":"Klimesch","year":"2012","journal-title":"Trends in Cognitive Sciences"},{"issue":"19","key":"10.1016\/j.pharmthera.2018.11.010_bb0625","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1007\/s00213-015-4026-7","article-title":"Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations","volume":"232","author":"Kometer","year":"2015","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.11.010_bb0630","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","article-title":"Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors","volume":"72","author":"Kometer","year":"2012","journal-title":"Biological Psychiatry"},{"issue":"25","key":"10.1016\/j.pharmthera.2018.11.010_bb0635","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","article-title":"Activation of serotonin 2A receptors underlies the psilocybin-induced effects on alpha oscillations, N170 visual-evoked potentials, and visual hallucinations","volume":"33","author":"Kometer","year":"2013","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0640","doi-asserted-by":"crossref","first-page":"e63972","DOI":"10.1371\/journal.pone.0063972","article-title":"Psychedelics and mental health: A population study","volume":"8","author":"Krebs","year":"2013","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.11.010_bb0645","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"12","key":"10.1016\/j.pharmthera.2018.11.010_bb0650","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.biopsych.2013.03.026","article-title":"Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond","volume":"73","author":"Krystal","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0655","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fnhum.2013.00323","article-title":"Rethinking the role of the rTPJ in attention and social cognition in light of the opposing domains hypothesis: Findings from an ALE-based meta-analysis and resting-state functional connectivity","volume":"7","author":"Kubit","year":"2013","journal-title":"Frontiers in Human Neuroscience"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.11.010_bb0660","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1523\/JNEUROSCI.5055-13.2014","article-title":"Enhanced medial prefrontal-default mode network functional connectivity in chronic pain and its association with pain rumination","volume":"34","author":"Kucyi","year":"2014","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0665","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-0028-1094301","article-title":"LSD in the treatment of alcoholics","volume":"4","author":"Kurland","year":"1971","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0670","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/02791072.1985.10524332","article-title":"LSD in the supportive care of the terminally ill cancer patient","volume":"17","author":"Kurland","year":"1985","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0675","series-title":"Patients with terminal cancer psychotheramacological agents for the terminally ill and bereaved","first-page":"86","article-title":"Psychedelic drug assisted psychotherapy","author":"Kurland","year":"1973"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0680","series-title":"The present status of psychotropic drugs: Pharmacological and clinical aspects","first-page":"432","article-title":"Psychedelic psychotherapy (LSD) in the treatment of the patient with a malignancy","author":"Kurland","year":"1969"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.11.010_bb0685","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","article-title":"Psychedelic drugs in biomedicine","volume":"38","author":"Kyzar","year":"2017","journal-title":"Trends in Pharmacological Sciences"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.11.010_bb0690","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/0269881114523866","article-title":"The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample","volume":"28","author":"Lawn","year":"2014","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0695","first-page":"29","article-title":"The effects of consciousness-expanding drugs on prisoner rehabilitation","volume":"10","author":"Leary","year":"1969","journal-title":"Psychedelic Review"},{"issue":"9","key":"10.1016\/j.pharmthera.2018.11.010_bb0700","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1002\/hbm.23234","article-title":"LSD-induced entropic brain activity predicts subsequent personality change","volume":"37","author":"Lebedev","year":"2016","journal-title":"Human Brain Mapping"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.11.010_bb0705","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1002\/hbm.22833","article-title":"Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin","volume":"36","author":"Lebedev","year":"2015","journal-title":"Human Brain Mapping"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0710","series-title":"Acid dreams: The complete social history of LSD: The CIA, the sixties, and beyond (revised Ed.)","author":"Lee","year":"1992"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0715","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/brain\/awt162","article-title":"The role of the posterior cingulate cortex in cognition and disease","volume":"137","author":"Leech","year":"2014","journal-title":"Brain: A Journal of Neurology"},{"issue":"12","key":"10.1016\/j.pharmthera.2018.11.010_bb0720","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.biopsych.2013.10.001","article-title":"Resting state functional connectivity and depression: In search of a bottom line","volume":"74","author":"Leibenluft","year":"2013","journal-title":"Biological Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.11.010_bb0725","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamapsychiatry.2013.4091","article-title":"Large-scale brain network coupling predicts acute nicotine abstinence effects on craving and cognitive function","volume":"71","author":"Lerman","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0730","first-page":"105","article-title":"New considerations regarding the identity of vedic s\u00f3ma as the mushroom fly-agaric","volume":"111","author":"Levitt","year":"2011","journal-title":"Studia Orientalia"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0735","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuroimage.2017.07.020","article-title":"Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow","volume":"159","author":"Lewis","year":"2017","journal-title":"NeuroImage"},{"issue":"9-10","key":"10.1016\/j.pharmthera.2018.11.010_bb0740","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00213-016-4453-0","article-title":"Alterations of consciousness and mystical-type experiences after acute LSD in humans","volume":"234","author":"Liechti","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0745","series-title":"Global drug survey key findings 2017","author":"Linstock","year":"2017"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0750","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3171\/2011.10.JNS102122","article-title":"A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression","volume":"116","author":"Lozano","year":"2012","journal-title":"Journal of Neurosurgery"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.11.010_bb0755","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1089\/brain.2014.0264","article-title":"Abstinence from cocaine and sucrose self-administration reveals altered mesocorticolimbic circuit connectivity by resting state MRI","volume":"4","author":"Lu","year":"2014","journal-title":"Brain Connectivity"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0760","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1176\/ajp.126.1.59","article-title":"A clinical study of LSD treatment in alcoholism","volume":"126","author":"Ludwig","year":"1969","journal-title":"American Journal of Psychiatry"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.11.010_bb0765","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness","volume":"25","author":"MacLean","year":"2011","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0770","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1468-5906.2012.01685.x","article-title":"Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin","volume":"51","author":"Maclean","year":"2012","journal-title":"Journal for the Scientific Study of Religion"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0775","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/2045125316676092","article-title":"Role of psilocybin in the treatment of depression","volume":"7","author":"Mahapatra","year":"2017","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0780","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0269881114568040","article-title":"Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?","volume":"29","author":"Majic","year":"2015","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0785","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/02791072.1998.10399714","article-title":"Treatment of alcoholism using psychedelic drugs: A review of the program of research","volume":"30","author":"Mangini","year":"1998","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0790","series-title":"Toward a psychology of being","author":"Maslow","year":"1968"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.11.010_bb0795","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.neuron.2005.02.014","article-title":"Deep brain stimulation for treatment-resistant depression","volume":"45","author":"Mayberg","year":"2005","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.pharmthera.2018.11.010_bb0800","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1177\/0269881116675771","article-title":"Psilocybin for depression and anxiety associated with life-threatening illnesses","volume":"30","author":"McCorvy","year":"2016","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0805","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/archpsyc.1971.01750070037005","article-title":"LSD revisited. A ten-year follow-up of medical LSD use","volume":"24","author":"McGlothlin","year":"1971","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0810","series-title":"Food of the gods: The search for the original tree of knowledge, A radical history of plants, drugs, and human evolution","author":"McKenna","year":"1993"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0815","series-title":"Monitoring the future study national survey results on drug use, 1975-2016: Volume 1, secondary school students","author":"Miech","year":"2017"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.11.010_bb0820","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/jclp.20000","article-title":"The phenomenon of quantum change","volume":"60","author":"Miller","year":"2004","journal-title":"Journal of Clinical Psychology"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0045","series-title":"Quantum change: When epiphanies and sudden insights transform ordinary lives","author":"Miller","year":"2001"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.11.010_bb0825","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1360-0443.1995.tb02235.x","article-title":"Alternative religion and outcome of alcohol dependence in Brazil","volume":"90","author":"Miranda","year":"1995","journal-title":"Addiction (Abingdon, England)"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.11.010_bb0830","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"7-8","key":"10.1016\/j.pharmthera.2018.11.010_bb0835","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/dta.1620","article-title":"From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs","volume":"6","author":"Morris","year":"2014","journal-title":"Drug Testing and Analysis"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.11.010_bb0840","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajmg.b.32177","article-title":"What can we learn about schizophrenia from studying the human model, drug-induced psychosis?","volume":"162","author":"Murray","year":"2013","journal-title":"American Journal of Medical Genetics Part B: Neuropsychiatric Genetics"},{"issue":"38","key":"10.1016\/j.pharmthera.2018.11.010_bb0845","doi-asserted-by":"crossref","first-page":"15171","DOI":"10.1523\/JNEUROSCI.2063-13.2013","article-title":"Broadband cortical desynchronization underlies the human psychedelic state","volume":"33","author":"Muthukumaraswamy","year":"2013","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0850","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacological Reviews"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.11.010_bb0855","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/jm00347a010","article-title":"Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes","volume":"25","author":"Nichols","year":"1982","journal-title":"Journal of Medicinal Chemistry"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.11.010_bb0860","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","article-title":"Effects of schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nature Reviews. Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0865","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1749-6632.1957.tb40738.x","article-title":"A review of the clinical effects of psychotomimetic agents","volume":"66","author":"Osmond","year":"1957","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0870","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report","volume":"37","author":"Os\u00f3rio","year":"2015","journal-title":"Revista Brasileira de Psiquiatria"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0875","series-title":"The use of LSD in psychotherapy and alcoholism","first-page":"629","article-title":"The contribution of the psychology of religion to the therapeutic use of the psychedelic substances","author":"Pahnke","year":"1967"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0880","series-title":"LSD man & society","first-page":"60","article-title":"LSD and religious experience","author":"Pahnke","year":"1967"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0885","series-title":"Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness","author":"Pahnke","year":"1963"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0890","first-page":"149","article-title":"Psychedelic drugs and mystical experience","volume":"5","author":"Pahnke","year":"1969","journal-title":"International Psychiatry Clinics"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0895","first-page":"144","article-title":"LSD-assisted psychotherapy with terminal cancer patients","volume":"9","author":"Pahnke","year":"1969","journal-title":"Current Psychiatric Therapies"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0900","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF01532646","article-title":"Implications of LSD and experimental mysticism","volume":"5","author":"Pahnke","year":"1966","journal-title":"Journal of Religion and Health"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0905","doi-asserted-by":"crossref","first-page":"e0118143","DOI":"10.1371\/journal.pone.0118143","article-title":"The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network","volume":"10","author":"Palhano-Fontes","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0910","first-page":"1","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","author":"Palhano-Fontes","year":"2018","journal-title":"Psychological Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0915","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addiction Biology"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0920","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajp.2016.08.010","article-title":"Return of the psychedelics: Psilocybin for treatment resistant depression","volume":"24","author":"Patra","year":"2016","journal-title":"Asian Journal of Psychiatry"},{"issue":"101","key":"10.1016\/j.pharmthera.2018.11.010_bb0925","doi-asserted-by":"crossref","first-page":"20140873","DOI":"10.1098\/rsif.2014.0873","article-title":"Homological scaffolds of brain functional networks","volume":"11","author":"Petri","year":"2014","journal-title":"Journal of the Royal Society, Interface"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.11.010_bb0930","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/0269881117691453","article-title":"The association of psychedelic use and opioid use disorders among illicit users in the United States","volume":"31","author":"Pisano","year":"2017","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0935","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.neuron.2011.09.006","article-title":"Functional network organization of the human brain","volume":"72","author":"Power","year":"2011","journal-title":"Neuron"},{"issue":"18","key":"10.1016\/j.pharmthera.2018.11.010_bb0940","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1073\/pnas.1524187113","article-title":"Effects of serotonin 2A\/1A receptor stimulation on social exclusion processing","volume":"113","author":"Preller","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0945","doi-asserted-by":"crossref","DOI":"10.1007\/7854_2016_459","article-title":"Phenomenology, structure, and dynamic of psychedelic states","author":"Preller","year":"2016","journal-title":"Current Topics in Behavioral Neurosciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0950","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.tics.2011.12.011","article-title":"Neural circuits underlying the pathophysiology of mood disorders","volume":"16","author":"Price","year":"2012","journal-title":"Trends in Cognitive Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0955","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1521-0391.2013.12083.x","article-title":"Prevalence of reported peyote use 1985-2010 effects of the American Indian Religious Freedom Act of 1994","volume":"23","author":"Prue","year":"2014","journal-title":"American Journal on Addictions"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb0960","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/npp.2011.228","article-title":"Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers","volume":"37","author":"Quednow","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0965","first-page":"660","article-title":"A computational model of major depression: The role of glutamate dysfunction on cingulo-frontal network dynamics","volume":"27","author":"Ramirez-Mahaluf","year":"2017","journal-title":"Cerebral Cortex (New York, N.Y.: 1991)"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb0970","series-title":"A nationwide study for the national commission on marihuana and drug abuse","article-title":"Drug experience, attitudes and related behavior among adolescents and adults: Detailed tabulations, part 2c. experience data","author":"Response Analysis Corporation","year":"1973"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0975","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000077946","article-title":"Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: A functional neuroimaging study using low-resolution electromagnetic tomography","volume":"50","author":"Riba","year":"2004","journal-title":"Neuropsychobiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.11.010_bb0980","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1365-2125.2002.01609.x","article-title":"Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers","volume":"53","author":"Riba","year":"2002","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb0985","first-page":"309","article-title":"Psychedelic drug-assisted psychotherapy with persons suffering from terminal cancer","volume":"5","author":"Richards","year":"1979","journal-title":"Journal of Altered States of Consciousness"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb0990","first-page":"121","article-title":"LSD-assisted psychotherapy and the human encounter with death","volume":"4","author":"Richards","year":"1972","journal-title":"The Journal of Transpersonal Psychology"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb0995","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.1977.10472020","article-title":"The peak experience variable in DPT-assisted psychotherapy with cancer patients","volume":"9","author":"Richards","year":"1977","journal-title":"Journal of Psychedelic Drugs"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb1000","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2190\/NGUB-V4RM-T7DC-XTH3","article-title":"DPT as an adjunct in brief psychotherapy with cancer patients","volume":"10","author":"Richards","year":"1979","journal-title":"OMEGA--Journal of Death and Dying"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1005","series-title":"Psychoactive sacramental: essays on etheogens and religion","author":"Roberts","year":"2001"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1010","article-title":"Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression","author":"Roseman","year":"2017","journal-title":"Neuropharmacology."},{"issue":"12","key":"10.1016\/j.pharmthera.2018.11.010_bb1015","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1020","series-title":"Life style and campus communities: A report of a survey of American colleges and universities (1969-70)","author":"Rossi","year":"1972"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.11.010_bb1025","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1017\/S1461145711001593","article-title":"An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression","volume":"15","author":"Salvadore","year":"2012","journal-title":"The International Journal of Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.11.010_bb1030","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrd2462","article-title":"Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders","volume":"7","author":"Sanacora","year":"2008","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb1035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study","volume":"36","author":"Sanches","year":"2016","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2018.11.010_bb1040","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict: A controlled study","volume":"28","author":"Savage","year":"1973","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1045","doi-asserted-by":"crossref","first-page":"46421","DOI":"10.1038\/srep46421","article-title":"Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin","volume":"7","author":"Schartner","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1050","series-title":"Plants of the gods: Their sacred, healing, and hallucinogenic powers (2nd ed., Rev. and expanded Ed.)","author":"Schultes","year":"2001"},{"issue":"3864","key":"10.1016\/j.pharmthera.2018.11.010_bb1055","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.163.3864.245","article-title":"Hallucinogens of plant origin","volume":"163","author":"Schultes","year":"1969","journal-title":"Science (New York, N.Y.)"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb1060","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.neuroimage.2004.01.015","article-title":"Limbic-frontal circuitry in major depression: A path modeling metanalysis","volume":"22","author":"Seminowicz","year":"2004","journal-title":"NeuroImage"},{"issue":"12","key":"10.1016\/j.pharmthera.2018.11.010_bb1065","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","article-title":"Response of cluster headache to psilocybin and LSD","volume":"66","author":"Sewell","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2018.11.010_bb1070","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cercor\/bhr099","article-title":"Decoding subject-driven cognitive states with whole-brain connectivity patterns","volume":"22","author":"Shirer","year":"2012","journal-title":"Cerebral Cortex (New York, N.Y.: 1991)"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1075","series-title":"PiHKAL","author":"Shulgin","year":"1991"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1080","series-title":"TiHKAL","author":"Shulgin","year":"1997"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.11.010_bb1085","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tips.2009.09.002","article-title":"Glutamate-based antidepressants: 20 years on","volume":"30","author":"Skolnick","year":"2009","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1090","series-title":"Cleansing the doors of perception: The religious significance of entheogenic plants and chemicals","author":"Smith","year":"2000"},{"issue":"31","key":"10.1016\/j.pharmthera.2018.11.010_bb1095","doi-asserted-by":"crossref","first-page":"13040","DOI":"10.1073\/pnas.0905267106","article-title":"Correspondence of the brain's functional architecture during activation and rest","volume":"106","author":"Smith","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb1100","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/0269881116628430","article-title":"Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide","volume":"30","author":"Speth","year":"2016","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"12","key":"10.1016\/j.pharmthera.2018.11.010_bb1105","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0006-3223(95)00418-1","article-title":"Increased activation of indirect semantic associations under psilocybin","volume":"39","author":"Spitzer","year":"1996","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1749-6632.2010.05888.x","article-title":"The human connectome: A complex network","volume":"1224","author":"Sporns","year":"2011","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1115","series-title":"The teachings of the mystics","author":"Stace","year":"1960"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1120","series-title":"Mysticism and philosophy","author":"Stace","year":"1960"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1125","series-title":"Storming heaven: LSD and the American dream","author":"Stevens","year":"1987"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb1130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","article-title":"Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects","volume":"51","author":"Strassman","year":"1994","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb1135","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.neuroimage.2012.01.117","article-title":"Resting state functional connectivity in addiction: Lessons learned and a road ahead","volume":"62","author":"Sutherland","year":"2012","journal-title":"NeuroImage"},{"issue":"12","key":"10.1016\/j.pharmthera.2018.11.010_bb1140","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.neuropsychologia.2006.05.023","article-title":"The functional neuroanatomy of autobiographical memory: A meta-analysis","volume":"44","author":"Svoboda","year":"2006","journal-title":"Neuropsychologia"},{"issue":"11","key":"10.1016\/j.pharmthera.2018.11.010_bb1145","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1002\/hbm.22562","article-title":"Enhanced repertoire of brain dynamical states during the psychedelic experience","volume":"35","author":"Tagliazucchi","year":"2014","journal-title":"Human Brain Mapping"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.11.010_bb1150","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cub.2016.02.010","article-title":"Increased global functional connectivity correlates with LSD-induced ego dissolution","volume":"26","author":"Tagliazucchi","year":"2016","journal-title":"Current Biology: CB"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1155","first-page":"459","article-title":"Group therapy with LSD-25. (A preliminary report)","volume":"22","author":"Tenenbaum","year":"1961","journal-title":"Diseases of the Nervous System"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb1160","doi-asserted-by":"crossref","first-page":"932","DOI":"10.15288\/qjsa.1970.31.932","article-title":"Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: A controlled evaluation","volume":"31","author":"Tomsovic","year":"1970","journal-title":"Quarterly Journal of Studies on Alcohol"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.11.010_bb1320","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.euroneuro.2016.03.012","article-title":"Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans","volume":"26","author":"Valle","year":"2016","journal-title":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2018.11.010_bb1325","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMra1511480","article-title":"Neurobiologic advances from the brain disease model of addiction","volume":"374","author":"Volkow","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2018.11.010_bb1330","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nature Reviews. Neuroscience"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.11.010_bb1335","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","article-title":"Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis","volume":"16","author":"Vollenweider","year":"1997","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"17","key":"10.1016\/j.pharmthera.2018.11.010_bb1340","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"issue":"5","key":"10.1016\/j.pharmthera.2018.11.010_bb1345","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","article-title":"5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride","volume":"20","author":"Vollenweider","year":"1999","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.11.010_bb1350","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/0269881116642538","article-title":"Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use","volume":"30","author":"Walsh","year":"2016","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1355","series-title":"The road to Eleusis. Unveiling the Secret of the Mysteries","author":"Wasson","year":"1978"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1360","first-page":"9","article-title":"Mixing the kykeon","volume":"4","author":"Webster","year":"2000","journal-title":"Eleusis: Journal of Psychoactive Plants and Compounds"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.11.010_bb1365","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/00952999809001545","article-title":"The pursuit of intoxication: Our 100 century-old romance with psychoactive substances","volume":"14","author":"Westermeyer","year":"1988","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00413101","article-title":"Cross tolerance between mescaline and LSD-25, with a comparison of the mescaline and LSD reactions","volume":"3","author":"Wolbach","year":"1962","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1375","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00412109","article-title":"Comparison of psilocin with psilocybin, mescaline and LSD-25","volume":"3","author":"Wolbach","year":"1962","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1380","author":"World Health Organization"},{"key":"10.1016\/j.pharmthera.2018.11.010_bb1385","series-title":"Psychology of religion (1. print. Ed.)","author":"Wulff","year":"1991"},{"issue":"3","key":"10.1016\/j.pharmthera.2018.11.010_bb1390","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1152\/jn.00338.2011","article-title":"The organization of the human cerebral cortex estimated by intrinsic functional connectivity","volume":"106","author":"Yeo","year":"2011","journal-title":"Journal of Neurophysiology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818302158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818302158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:02:23Z","timestamp":1759010543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725818302158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":250,"alternative-id":["S0163725818302158"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.11.010","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}